Cantor Fitzgerald Estimates RARE FY2026 Earnings

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) - Analysts at Cantor Fitzgerald issued their FY2026 earnings per share estimates for shares of Ultragenyx Pharmaceutical in a research report issued on Monday, June 9th. Cantor Fitzgerald analyst K. Kluska expects that the biopharmaceutical company will earn ($2.61) per share for the year. Cantor Fitzgerald has a "Overweight" rating and a $118.00 price objective on the stock. The consensus estimate for Ultragenyx Pharmaceutical's current full-year earnings is ($5.18) per share.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last released its earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($1.57) earnings per share for the quarter, missing analysts' consensus estimates of ($1.54) by ($0.03). Ultragenyx Pharmaceutical had a negative return on equity of 193.80% and a negative net margin of 101.60%. The firm had revenue of $139.29 million for the quarter, compared to analysts' expectations of $145.98 million. During the same quarter in the previous year, the company posted ($2.03) earnings per share. The firm's quarterly revenue was up 28.0% on a year-over-year basis.

Other analysts have also recently issued reports about the company. Canaccord Genuity Group raised their price target on Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the company a "buy" rating in a research note on Tuesday, February 18th. JPMorgan Chase & Co. boosted their target price on Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the stock an "overweight" rating in a research note on Thursday, March 27th. William Blair assumed coverage on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, May 28th. They set an "outperform" rating and a $65.00 price objective for the company. Piper Sandler lowered their target price on shares of Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an "overweight" rating for the company in a report on Monday, March 17th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $95.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Friday, February 14th. One investment analyst has rated the stock with a hold rating and twelve have given a buy rating to the company's stock. According to data from MarketBeat, Ultragenyx Pharmaceutical presently has an average rating of "Moderate Buy" and a consensus price target of $88.77.

Ultragenyx Pharmaceutical Price Performance

Shares of Ultragenyx Pharmaceutical stock traded down $1.80 during trading on Tuesday, hitting $37.49. 1,094,008 shares of the stock were exchanged, compared to its average volume of 854,670. The firm's 50-day moving average price is $36.04 and its 200 day moving average price is $40.08. The stock has a market cap of $3.54 billion, a price-to-earnings ratio of -5.91 and a beta of 0.25. Ultragenyx Pharmaceutical has a 12-month low of $29.59 and a 12-month high of $60.37.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

Hedge funds have recently made changes to their positions in the business. Deep Track Capital LP purchased a new stake in Ultragenyx Pharmaceutical during the 4th quarter valued at approximately $27,493,000. Dark Forest Capital Management LP acquired a new position in shares of Ultragenyx Pharmaceutical in the fourth quarter valued at approximately $459,000. First Light Asset Management LLC raised its stake in shares of Ultragenyx Pharmaceutical by 1.1% during the fourth quarter. First Light Asset Management LLC now owns 763,607 shares of the biopharmaceutical company's stock worth $32,125,000 after purchasing an additional 8,505 shares during the last quarter. Stifel Financial Corp raised its stake in shares of Ultragenyx Pharmaceutical by 13.5% during the fourth quarter. Stifel Financial Corp now owns 23,796 shares of the biopharmaceutical company's stock worth $1,001,000 after purchasing an additional 2,835 shares during the last quarter. Finally, Alyeska Investment Group L.P. lifted its holdings in shares of Ultragenyx Pharmaceutical by 23.1% during the fourth quarter. Alyeska Investment Group L.P. now owns 1,439,740 shares of the biopharmaceutical company's stock worth $60,570,000 after purchasing an additional 269,733 shares during the period. Institutional investors and hedge funds own 97.67% of the company's stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.